[HTML][HTML] Comparison of different tyrosine kinase inhibitors for treatment of poor performance status patients with EGFR-mutated lung adenocarcinoma
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - Cancers, 2022 - mdpi.com
Simple Summary Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
are standard treatments in patients with EGFR-mutated lung adenocarcinoma. However, the …
are standard treatments in patients with EGFR-mutated lung adenocarcinoma. However, the …
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma.
CE Wu, CF Chang, CY Huang, CT Yang, CS Kuo… - Cancers, 2022 - europepmc.org
The aim of this retrospective study was to investigate the tolerability and survival outcomes
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
CE Wu, C Ching-Fu, H Chen-Yang, Y Cheng-Ta… - …, 2022 - search.proquest.com
The aim of this retrospective study was to investigate the tolerability and survival outcomes
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - …, 2022 - pure.lib.cgu.edu.tw
摘要The aim of this retrospective study was to investigate the tolerability and survival
outcomes of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) …
outcomes of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) …
[HTML][HTML] Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - Cancers, 2022 - ncbi.nlm.nih.gov
The aim of this retrospective study was to investigate the tolerability and survival outcomes
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
CE Wu, CF Chang, CY Huang, CT Yang… - …, 2022 - pubmed.ncbi.nlm.nih.gov
The aim of this retrospective study was to investigate the tolerability and survival outcomes
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma.
CE Wu, CF Chang, CY Huang, CT Yang, CS Kuo… - Cancers, 2022 - europepmc.org
The aim of this retrospective study was to investigate the tolerability and survival outcomes
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - …, 2022 - pure.lib.cgu.edu.tw
The aim of this retrospective study was to investigate the tolerability and survival outcomes
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …
of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in …